A Phase 3 interventional study of AFLIBERCEPT AVE0005 and FOLFIRI in Colorectal Cancer Metastatic, sponsored by Sanofi. Completed at 179 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-17.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing aflibercept in Colorectal Neoplasms — 1 open to participants now, 2 under way, none of them phase 3. aflibercept · Colorectal Neoplasms.
Among the 24 studies testing aflibercept in Colorectal Neoplasms, this one is the 2nd largest by enrollment, is one of 7 that started in 2012, is one of 4 in phase 3, and was the 4th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →1 of the 24 studies testing aflibercept in Colorectal Neoplasms is open now, in 1 country. Recruiting first, the newest first:
Yonsei University · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 17 · Phase 3 5 · Phase 4 1
First in 2007; this study’s year is marked. 7 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 781 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 63 across the 24 interventional studies. Of the 17 that completed or were terminated, 12 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 24 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
24 studies in Colorectal Neoplasms by Sanofi: 1 open now, 1 under way, none of them phase 3. Of 20 finished, 9 (45%) have results posted.
Among the 24 studies in Colorectal Neoplasms by Sanofi, this one is the 3rd largest by enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2012, is one of 10 in phase 3, and was the 16th registered.
Sanofi’s Colorectal Neoplasms studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 24 studies testing aflibercept in Colorectal Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 24 in Colorectal Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To provide metastatic colorectal cancer participants with access to aflibercept and to document the overall safety in these participants
Secondary Objective:
To document the Health-Related Quality of Life of aflibercept in this participants population
Each participants will be treated until disease progression, unacceptable toxicity, death, Investigator's decision or participant's refusal for further treatment (whichever comes first). Participants were followed-up during study treatment and for at least 30 days after last administration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information wass not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Aflibercept 4 mg/kg IV infusion over 60 minutes followed by Irinotecan 180 mg/m\^2 IV infusion over 90 minutes and Leucovorin 400 mg/m\^2 IV infusion over 120 minutes at the same time followed by 5-Fluorouracil (5-FU) 400 mg/m\^2 IV bolus over 2-4 minutes followed by 5-FU 2400 mg/m\^2 continuous IV infusion over 46 hours on Day 1 of each cycle (1 Cycle = 2 weeks), until disease progression (DP), unacceptable toxicity, death, Investigator's decision or participant's refusal of further treatment.
Drug: AFLIBERCEPT AVE0005 · Drug: FOLFIRI
Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous
irinotecan, 5-FU and leucovorin
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an adverse event (AE) without regard to possibility of causal relationship with this treatment. A serious AE (SAE): Any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. National Cancer Institute Common Terminology Criteria (NCI-CTCAE) Version 4.03 was used to assess severity (Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling) of AEs.
Time frame: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
Number of Participants With Abnormal Hematological Parameters
Abnormal hematological parameters included: anaemia, thrombocytopenia, leukopenia and neutropenia. Number of participants with each of these parameters were analyzed by grades (All Grades and Grades 3-4 as per NCI CTCAE (Version 4.03), where Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4.
Time frame: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
Number of Participants With International Normalized Ratio (INR)
The INR is a derived measure of the prothrombin time. The INR is the ratio of a participant's prothrombin time to a normal control sample. Normal range (without anti coagulation therapy): 0.8-1.2; Targeted range (with anti coagulation therapy) 2.0-3.0.
Time frame: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
Number of Participants With Abnormal Electrolytes Parameters
Abnormal electrolytes parameters included: hyponatremia, hypernatremia, hypocalcemia, hypercalcemia, hypokalemia, and hyperkalemia. Number of participants with each of these parameters were analyzed by grades ( All Grades and Grades 3-4 as per NCI CTCAE Version 4.03, where Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4.
Time frame: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
Number of Participants With Abnormal Renal and Liver Function Parameters
Renal and liver function parameters included: creatinine, hyperbilirubinemia, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase. Number of participants with each of these parameters were analyzed by grades (All Grades and Grades 3-4) as per NCI CTCAE version 4.03, where Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4.
Time frame: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
Creatinine Clearance of Aflibercept Plus FOLFIRI
Creatinine clearance is a measure of kidney function. Creatinine clearance rate is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Creatinine clearance can be measured directly or estimated using established formulas. For this study, the creatinine clearance was calculated using the Cockroft-Gault or Modification of Diet in Renal Disease (MDRD).
Time frame: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
Number of Participants With Other Abnormal Biochemistry Parameters
Other abnormal biochemistry parameters included: hypoglycemia, hyperglycemia and hypoalbuminemia. Number of participants with each of these parameters were analyzed by grades (All Grades and Grades 3-4) as per NCI CTCAE Version 4.03, where Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4.
Time frame: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
Number of Participants With Abnormal Non-Gradable Biochemistry Parameters
Non-gradeable biochemistry parameters included; chloride, urea, total protein, blood urea nitrogen (BUN) and lactate dehydrogenase (LDH). Number of participants with \<lower limit of normal ranges (LLN) and \>upper limit of normal ranges (ULN) for each of these parameters were reported.
Time frame: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
Number of Participants With Proteinuria Events
Proteinuria is defined as the ratio of protein to creatinine. Number of participants with proteinuria were analyzed by grades (Grades 1, 2, 3 ,4) as per NCI CTCAE Version 4.03 where Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling.
Time frame: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
Number of Participants With Proteinuria Grade >=2
Proteinuria is defined as the ratio of protein to creatinine. Number of participants with proteinuria grade \>=2 (graded as per NCI CTCAE Version 4.03), where Grade\>=2 represents moderate to life-threatening/disabling event.
Time frame: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
Number of Participants With Urinary Protein-Creatinine Ratio (UPCR)
Urinary protein creatinine ratio (UPCR) corresponds to the ratio of the urinary protein and urinary creatinine concentration (expressed in mg/dL). This ratio provides an accurate quantification of 24-hours urinary protein excretion. There is a high correlation between morning UPCR and 24-hour proteinuria in participants with normal or reduced renal functions. Normal ratio is \< or = 1.
Time frame: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
Number of Participants With Proteinuria (Grade>=2) Concomitant With Hematuria and /or Hypertension
Proteinuria is defined as the presence of excess proteins in the urine (assessed either by spot sample, dipstick/ urine protein or 24 hour urine collection). Hematuria is defined as the presence of blood in urine (positive dipstick for RBC or reported AE). Number of participants with proteinuria grade \>=2 (graded as per NCI CTCAE Version 4.03), where Grade\>=2 represents moderate to life-threatening/disabling event. Hypertension (high blood pressure) is defined as having a blood pressure reading of more than 140/90 mmHg over a number of weeks.
Time frame: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
Number of Participants With Cycle Delay and/or Dose Modification
A theoretical cycle is a 2 week period i.e. 14 days. A cycle is delayed if duration of previous cycle is greater than 14+2 days ; dose modification includes dose reduction and dose omission.
Time frame: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
Mean Change From Baseline in Health Related Quality of Life (HRQL) European Organization for Research and Treatment for Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30 Score): Global Health Status
EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) \& other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health \& quality of life, coded on 7-point scale (1=very poor to 7=excellent).EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 \& 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favourable outcome with a best quality of life for participant.
Time frame: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at the end of treatment (EOT) (within 30 days of last treatment) (maximum exposure: 214 weeks)
Mean Change From Baseline in HRQL EORTC QLQ-C30 Score: Functional Scales
EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) \& other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health \& quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 \& 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28).Answers were converted into grading scale, with values between 0 and 100. A high score represented a favourable outcome with a best quality of life for participant.
Time frame: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)
Change From Baseline in HRQL EORTC QLQ-C30 Score: Symptom Scales
EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) \& other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health \& quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 \& 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favorable outcome with a best quality of life for participant.
Time frame: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)
Change From Baseline in HRQL EQ-5D-3L Quality of Life: Single Index Utility Score
EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and Visual Analogue Scale (VAS). EQ-5D descriptive system comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression measured on 3 levels (no problem, some problems \& severe problems) within a particular EQ-5D dimension. 5 dimensional 3-level system was converted into single index utility score. Possible values for single index utility score ranged from -0.594 (severe problems in all dimensions) to 1.0 (no problem in all dimensions) on scale where 1 represented best possible health state.
Time frame: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)
Change From Baseline in HRQL EQ-5D-3L VAS Score
EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and VAS. EQ-5D descriptive system comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression measured on 3 levels (no problem, some problems \& severe problems) within a particular EQ-5D dimension. 5 dimensional 3-level system was converted into single index utility score. The VAS recorded the respondent's self-rated health on a vertical visual analogue scale. The VAS 'thermometer' has endpoints of 100 (Best imaginable health state) at the top and 0 (Worst imaginable health state) at the bottom. This information can be used as a quantitative measure of health outcome as judged by the individual respondents.
Time frame: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)
The study was conducted at 151 sites in 23 countries. A total of 798 participants were screened between 30 May 2012 and 03 January 2015, out of which 781 participants were enrolled and 779 participants were treated.
| Milestone | Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) |
|---|---|
| Started | 781 |
| Safety population | 779 |
| Completed | 612 |
| Not completed | 169 |
| Withdrew: Participant's decision | 84 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Enrolled but not treated | 2 |
| Withdrew: Other than specified above | 80 |
Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an adverse event (AE) without regard to possibility of causal relationship with this treatment. A serious AE (SAE): Any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. National Cancer Institute Common Terminology Criteria (NCI-CTCAE) Version 4.03 was used to assess severity (Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling) of AEs.
| Participants | Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) |
|---|---|
| Any TEAE (All Grades) | 769 |
| Any TEAEs (Grades 3-4) | 609 |
| Any serious TEAE | 272 |
| Any serious related TEAE | 159 |
| Any TEAE leading to death | 47 |
| Any TEAE (permanent treatment discontinuation) | 208 |
| Any TEAE (premature treatment discontinuation) | 104 |
Abnormal hematological parameters included: anaemia, thrombocytopenia, leukopenia and neutropenia. Number of participants with each of these parameters were analyzed by grades (All Grades and Grades 3-4 as per NCI CTCAE (Version 4.03), where Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4.
| Participants | Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) |
|---|---|
| Anaemia: All Grades | 535 |
| Anaemia: Grades 3-4 | 14 |
| Thrombocytopenia: All Grades | 293 |
| Thrombocytopenia: Grades 3-4 | 13 |
| Leukopenia: All Grades | 532 |
| Leukopenia: Grades 3-4 | 72 |
| Neutropenia: All Grades | 450 |
| Neutropenia: Grades 3-4 | 227 |
The INR is a derived measure of the prothrombin time. The INR is the ratio of a participant's prothrombin time to a normal control sample. Normal range (without anti coagulation therapy): 0.8-1.2; Targeted range (with anti coagulation therapy) 2.0-3.0.
| Participants | Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) |
|---|---|
| INR<1.5 | 106 |
| INR>=1.5 to <3 | 0 |
| INR>=3 to <5 | 2 |
| INR>=5 | 2 |
Abnormal electrolytes parameters included: hyponatremia, hypernatremia, hypocalcemia, hypercalcemia, hypokalemia, and hyperkalemia. Number of participants with each of these parameters were analyzed by grades ( All Grades and Grades 3-4 as per NCI CTCAE Version 4.03, where Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4.
| Participants | Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) |
|---|---|
| Hyponatremia: All Grades | 181 |
| Hyponatremia: Grades 3-4 | 32 |
| Hypernatremia: All Grades | 75 |
| Hypernatremia: Grades 3-4 | 1 |
| Hypocalcemia: All Grades | 213 |
| Hypocalcemia: Grades 3-4 | 5 |
| Hypercalcemia: All Grades | 52 |
| Hypercalcemia: Grades 3-4 | 2 |
| Hypokalemia: All Grades | 121 |
| Hypokalemia: Grades 3-4 | 16 |
| Hyperkalemia: All Grades | 166 |
| Hyperkalemia: Grades 3-4 | 10 |
Renal and liver function parameters included: creatinine, hyperbilirubinemia, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase. Number of participants with each of these parameters were analyzed by grades (All Grades and Grades 3-4) as per NCI CTCAE version 4.03, where Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4.
| Participants | Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) |
|---|---|
| Creatinine: All Grades | 161 |
| Creatinine: Grades 3-4 | 2 |
| Hyperbilirubinemia: All Grades | 130 |
| Hyperbilirubinemia: Grades 3-4 | 9 |
| AST: All Grades | 342 |
| AST: Grades 3-4 | 12 |
| ALT: All Grades | 270 |
| ALT: Grades 3-4 | 10 |
| Alkaline phosphatase: All Grades | 465 |
| Alkaline phosphatase: Grades 3-4 | 23 |
Creatinine clearance is a measure of kidney function. Creatinine clearance rate is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Creatinine clearance can be measured directly or estimated using established formulas. For this study, the creatinine clearance was calculated using the Cockroft-Gault or Modification of Diet in Renal Disease (MDRD).
| mL/min | Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) |
|---|---|
| Creatinine Clearance of Aflibercept Plus FOLFIRI | 71.4 ± 29.3 |
Other abnormal biochemistry parameters included: hypoglycemia, hyperglycemia and hypoalbuminemia. Number of participants with each of these parameters were analyzed by grades (All Grades and Grades 3-4) as per NCI CTCAE Version 4.03, where Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4.
| Participants | Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) |
|---|---|
| Hypoglycemia: All Grades | 90 |
| Hypoglycemia: Grades 3-4 | 6 |
| Hyperglycemia: All Grades | 403 |
| Hyperglycemia: Grades 3-4 | 30 |
| Hypoalbuminemia: All Grades | 241 |
| Hypoalbuminemia: Grades 3-4 | 6 |
Non-gradeable biochemistry parameters included; chloride, urea, total protein, blood urea nitrogen (BUN) and lactate dehydrogenase (LDH). Number of participants with \<lower limit of normal ranges (LLN) and \>upper limit of normal ranges (ULN) for each of these parameters were reported.
| Participants | Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) |
|---|---|
| Chloride<LLN | 135 |
| Chloride>ULN | 217 |
| BUN<LLN | 41 |
| BUN>ULN | 83 |
| UREA<LLN | 60 |
| UREA>ULN | 250 |
| LDH<LLN | 79 |
| LDH>ULN | 423 |
| Total proteins<LLN | 162 |
| Total proteins>ULN | 77 |
Proteinuria is defined as the ratio of protein to creatinine. Number of participants with proteinuria were analyzed by grades (Grades 1, 2, 3 ,4) as per NCI CTCAE Version 4.03 where Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling.
| Participants | Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) |
|---|---|
| Grade 1 | 286 |
| Grade 2 | 123 |
| Grade 3 | 54 |
| Grade 4 | 5 |
Proteinuria is defined as the ratio of protein to creatinine. Number of participants with proteinuria grade \>=2 (graded as per NCI CTCAE Version 4.03), where Grade\>=2 represents moderate to life-threatening/disabling event.
| participants | Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) |
|---|---|
| Number of Participants With Proteinuria Grade >=2 | 182 |
Urinary protein creatinine ratio (UPCR) corresponds to the ratio of the urinary protein and urinary creatinine concentration (expressed in mg/dL). This ratio provides an accurate quantification of 24-hours urinary protein excretion. There is a high correlation between morning UPCR and 24-hour proteinuria in participants with normal or reduced renal functions. Normal ratio is \< or = 1.
| Participants | Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) |
|---|---|
| UPCR<=1 | 265 |
| UPCR>=1 to <=2 | 51 |
| UPCR>=2 to <=3 | 24 |
| UPCR>3 | 27 |
Proteinuria is defined as the presence of excess proteins in the urine (assessed either by spot sample, dipstick/ urine protein or 24 hour urine collection). Hematuria is defined as the presence of blood in urine (positive dipstick for RBC or reported AE). Number of participants with proteinuria grade \>=2 (graded as per NCI CTCAE Version 4.03), where Grade\>=2 represents moderate to life-threatening/disabling event. Hypertension (high blood pressure) is defined as having a blood pressure reading of more than 140/90 mmHg over a number of weeks.
| Participants | Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) |
|---|---|
| Proteinuria with hematuria | 72 |
| Proteinuria with hypertension | 4 |
| Proteinuria with hematuria and hypertension | 3 |
A theoretical cycle is a 2 week period i.e. 14 days. A cycle is delayed if duration of previous cycle is greater than 14+2 days ; dose modification includes dose reduction and dose omission.
| Participants | Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) |
|---|---|
| No delay and no dose modification | 119 |
| Any delay and/or dose modification | 660 |
| Delay only | 163 |
| Delay and Aflibercept modified | 39 |
| Delay and FOLFIRI modified | 308 |
| Delay and Aflibercept and Folfiri modified | 97 |
| Only Aflibercept modified | 5 |
| Only FOLFIRI modified | 43 |
| Both Aflibercept and FOLFIRI modified | 5 |
EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) \& other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health \& quality of life, coded on 7-point scale (1=very poor to 7=excellent).EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 \& 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favourable outcome with a best quality of life for participant.
| units on a scale | Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) |
|---|---|
| Baseline | 68.61 ± 20.48 |
| Change at Cycle 3 | -3.34 ± 18.83 |
| Change at Cycle 5 | -4.70 ± 18.89 |
| Change at Cycle 7 | -3.63 ± 22.02 |
| Change at Cycle 9 | -3.97 ± 21.31 |
| Change at Cycle 11 | -5.85 ± 22.26 |
| Change at Cycle 13 | -2.26 ± 21.69 |
| Change at Cycle 15 | -3.05 ± 22.46 |
| Change at Cycle 17 | -1.18 ± 22.50 |
| Change at Cycle 19 | -2.36 ± 22.92 |
| Change at Cycle 21 | -5.56 ± 23.77 |
| Change at Cycle 23 | -6.86 ± 19.94 |
| Change at Cycle 25 | -8.05 ± 16.89 |
| Change at Cycle 27 | -10.14 ± 17.58 |
| Change at Cycle 29 | -8.33 ± 14.05 |
| Change at Cycle 31 | -9.44 ± 16.92 |
| Change at Cycle 33 | -11.36 ± 21.82 |
| Change at Cycle 35 | -5.83 ± 20.81 |
| Change at EOT | -8.82 ± 23.95 |
EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) \& other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health \& quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 \& 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28).Answers were converted into grading scale, with values between 0 and 100. A high score represented a favourable outcome with a best quality of life for participant.
| units on a scale | Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) |
|---|---|
| Physical - Baseline | 81.79 ± 19.41 |
| Physical - Change at Cycle 3 | -3.73 ± 15.15 |
| Physical - Change at Cycle 5 | -3.95 ± 15.22 |
| Physical - Change at Cycle 7 | -4.62 ± 16.23 |
| Physical - Change at Cycle 9 | -4.36 ± 15.79 |
| Physical - Change at Cycle 11 | -6.99 ± 17.89 |
| Physical - Change at Cycle 13 | -4.99 ± 16.17 |
| Physical - Change at Cycle 15 | -3.54 ± 15.99 |
| Physical - Change at Cycle 17 | -5.10 ± 16.20 |
| Physical - Change at Cycle 19 | -5.68 ± 16.23 |
| Physical - Change at Cycle 21 | -5.70 ± 13.01 |
| Physical - Change at Cycle 23 | -7.87 ± 14.38 |
| Physical - Change at Cycle 25 | -5.75 ± 12.18 |
| Physical - Change at Cycle 27 | -6.59 ± 11.64 |
| Physical - Change at Cycle 29 | -7.67 ± 11.09 |
| Physical - Change at Cycle 31 | -9.33 ± 14.65 |
| Physical - Change at Cycle 33 | -5.45 ± 9.81 |
| Physical - Change at Cycle 35 | -10.00 ± 13.05 |
| Physical - Change at EOT | -11.16 ± 21.65 |
| Role - Baseline | 79.91 ± 26.25 |
| Role - Change at Cycle 3 | -6.26 ± 25.22 |
| Role - Change at Cycle 5 | -5.66 ± 23.26 |
| Role - Change at Cycle 7 | -6.68 ± 24.29 |
| Role - Change at Cycle 9 | -6.55 ± 23.95 |
| Role - Change at Cycle 11 | -8.76 ± 26.35 |
| Role - Change at Cycle 13 | -7.36 ± 23.41 |
| Role - Change at Cycle 15 | -7.18 ± 21.98 |
| Role - Change at Cycle 17 | -9.58 ± 22.54 |
| Role - Change at Cycle 19 | -9.84 ± 22.44 |
| Role - Change at Cycle 21 | -9.78 ± 18.11 |
| Role - Change at Cycle 23 | -10.65 ± 18.32 |
| Role - Change at Cycle 25 | -10.92 ± 17.97 |
| Role - Change at Cycle 27 | -10.14 ± 17.22 |
| Role - Change at Cycle 29 | -10.83 ± 17.33 |
| Role - Change at Cycle 31 | -14.44 ± 18.76 |
| Role - Change at Cycle 33 | -15.15 ± 15.73 |
| Role - Change at Cycle 35 | -15.00 ± 16.57 |
| Role - Change at EOT | -12.11 ± 28.22 |
| Emotional - Baseline | 78.96 ± 20.60 |
| Emotional - Change at Cycle 3 | 1.14 ± 19.95 |
| Emotional - Change at Cycle 5 | 0.74 ± 19.32 |
| Emotional - Change at Cycle 7 | 1.58 ± 20.91 |
| Emotional - Change at Cycle 9 | 1.69 ± 21.38 |
| Emotional - Change at Cycle 11 | 0.08 ± 20.40 |
| Emotional - Change at Cycle 13 | 0.93 ± 20.08 |
| Emotional - Change at Cycle 15 | 2.51 ± 20.23 |
| Emotional - Change at Cycle 17 | 2.91 ± 18.23 |
| Emotional - Change at Cycle 19 | 1.39 ± 17.60 |
| Emotional - Change at Cycle 21 | 0.06 ± 17.86 |
| Emotional - Change at Cycle 23 | 1.75 ± 19.29 |
| Emotional - Change at Cycle 25 | 4.98 ± 15.86 |
| Emotional - Change at Cycle 27 | 1.57 ± 17.64 |
| Emotional - Change at Cycle 29 | 2.64 ± 17.88 |
| Emotional - Change at Cycle 31 | 1.30 ± 17.78 |
| Emotional - Change at Cycle 33 | 0.25 ± 3.82 |
| Emotional - Change at Cycle 35 | -0.00 ± 5.56 |
| Emotional - Change at EOT | -2.87 ± 22.52 |
| Cognitive - Baseline | 86.90 ± 19.26 |
| Cognitive - Change at Cycle 3 | -1.77 ± 16.92 |
| Cognitive - Change at Cycle 5 | -1.87 ± 16.58 |
| Cognitive - Change at Cycle 7 | -1.99 ± 19.71 |
| Cognitive - Change at Cycle 9 | -2.18 ± 20.17 |
| Cognitive - Change at Cycle 11 | -4.27 ± 20.29 |
| Cognitive - Change at Cycle 13 | -2.83 ± 17.40 |
| Cognitive - Change at Cycle 15 | -2.28 ± 19.40 |
| Cognitive - Change at Cycle 17 | -3.45 ± 19.38 |
| Cognitive - Change at Cycle 19 | -5.00 ± 22.19 |
| Cognitive - Change at Cycle 21 | -5.56 ± 16.28 |
| Cognitive - Change at Cycle 23 | -5.71 ± 14.54 |
| Cognitive - Change at Cycle 25 | -6.90 ± 21.14 |
| Cognitive - Change at Cycle 27 | -5.80 ± 16.37 |
| Cognitive - Change at Cycle 29 | -6.67 ± 18.26 |
| Cognitive - Change at Cycle 31 | -5.56 ± 15.00 |
| Cognitive - Change at Cycle 33 | -10.61 ± 17.12 |
| Cognitive - Change at Cycle 35 | -11.67 ± 13.72 |
| Cognitive- Change at EOT | -4.98 ± 22.67 |
| Social - Baseline | 80.57 ± 24.68 |
| Social - Change at Cycle 3 | -2.05 ± 22.83 |
| Social - Change at Cycle 5 | -2.86 ± 21.60 |
| Social - Change at Cycle 7 | -4.78 ± 23.65 |
| Social - Change at Cycle 9 | -4.56 ± 23.84 |
| Social - Change at Cycle 11 | -7.09 ± 24.83 |
| Social - Change at Cycle 13 | -5.56 ± 24.03 |
| Social - Change at Cycle 15 | -6.18 ± 23.23 |
| Social - Change at Cycle 17 | -5.56 ± 22.69 |
| Social - Change at Cycle 19 | -5.28 ± 22.02 |
| Social - Change at Cycle 21 | -5.56 ± 21.61 |
| Social - Change at Cycle 23 | -7.62 ± 17.78 |
| Social - Change at Cycle 25 | -4.60 ± 18.31 |
| Social - Change at Cycle 27 | -2.17 ± 17.63 |
| Social - Change at Cycle 29 | -5.00 ± 18.81 |
| Social - Change at Cycle 31 | -7.78 ± 25.09 |
| Social - Change at Cycle 33 | -1.52 ± 17.41 |
| Social - Change at Cycle 35 | -1.67 ± 14.59 |
| Social - Change at EOT | -9.01 ± 26.23 |
EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) \& other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health \& quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 \& 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favorable outcome with a best quality of life for participant.
| units on a scale | Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) |
|---|---|
| Fatigue - Baseline | 29.16 ± 23.48 |
| Fatigue - Change at Cycle 3 | 7.35 ± 21.62 |
| Fatigue - Change at Cycle 5 | 8.40 ± 21.88 |
| Fatigue - Change at Cycle 7 | 9.54 ± 22.60 |
| Fatigue - Change at Cycle 9 | 7.89 ± 21.80 |
| Fatigue - Change at Cycle 11 | 11.30 ± 23.73 |
| Fatigue - Change at Cycle 13 | 8.33 ± 21.72 |
| Fatigue - Change at Cycle 15 | 7.41 ± 22.38 |
| Fatigue - Change at Cycle 17 | 6.70 ± 21.25 |
| Fatigue - Change at Cycle 19 | 8.93 ± 19.83 |
| Fatigue - Change at Cycle 21 | 10.39 ± 17.90 |
| Fatigue - Change at Cycle 23 | 10.80 ± 18.49 |
| Fatigue - Change at Cycle 25 | 7.66 ± 19.94 |
| Fatigue - Change at Cycle 27 | 9.66 ± 18.74 |
| Fatigue - Change at Cycle 29 | 11.67 ± 18.55 |
| Fatigue - Change at Cycle 31 | 14.07 ± 21.61 |
| Fatigue - Change at Cycle 33 | 15.15 ± 21.81 |
| Fatigue - Change at Cycle 35 | 14.44 ± 18.92 |
| Fatigue - Change at EOT | 12.31 ± 25.56 |
| Nausea and Vomiting - Baseline | 5.88 ± 13.99 |
| Nausea and Vomiting - Change at Cycle 3 | 6.68 ± 19.81 |
| Nausea and Vomiting - Change at Cycle 5 | 6.98 ± 19.79 |
| Nausea and Vomiting - Change at Cycle 7 | 6.61 ± 18.07 |
| Nausea and Vomiting - Change at Cycle 9 | 6.20 ± 19.68 |
| Nausea and Vomiting - Change at Cycle 11 | 8.97 ± 19.83 |
| Nausea and Vomiting - Change at Cycle 13 | 6.82 ± 14.71 |
| Nausea and Vomiting - Change at Cycle 15 | 6.85 ± 16.33 |
| Nausea and Vomiting - Change at Cycle 17 | 3.45 ± 15.49 |
| Nausea and Vomiting - Change at Cycle 19 | 6.56 ± 14.04 |
| Nausea and Vomiting - Change at Cycle 21 | 3.99 ± 14.14 |
| Nausea and Vomiting - Change at Cycle 23 | 7.87 ± 10.90 |
| Nausea and Vomiting - Change at Cycle 25 | 4.02 ± 8.52 |
| Nausea and Vomiting - Change at Cycle 27 | 7.25 ± 11.04 |
| Nausea and Vomiting - Change at Cycle 29 | 1.67 ± 5.13 |
| Nausea and Vomiting - Change at Cycle 31 | 13.33 ± 28.31 |
| Nausea and Vomiting - Change at Cycle 33 | 3.03 ± 6.74 |
| Nausea and Vomiting - Change at Cycle 35 | 3.33 ± 7.03 |
| Nausea and Vomiting - Change at EOT | 6.64 ± 21.11 |
| Pain - Baseline | 20.47 ± 25.08 |
| Pain - Change at Cycle 3 | 2.68 ± 25.02 |
| Pain - Change at Cycle 5 | 2.52 ± 23.48 |
| Pain - Change at Cycle 7 | 3.00 ± 24.98 |
| Pain - Change at Cycle 9 | 2.72 ± 24.45 |
| Pain - Change at Cycle 11 | 6.64 ± 23.68 |
| Pain - Change at Cycle 13 | 5.16 ± 19.79 |
| Pain - Change at Cycle 15 | 7.26 ± 21.91 |
| Pain - Change at Cycle 17 | 9.39 ± 22.97 |
| Pain - Change at Cycle 19 | 8.74 ± 22.28 |
| Pain - Change at Cycle 21 | 7.25 ± 18.14 |
| Pain - Change at Cycle 23 | 8.33 ± 19.31 |
| Pain - Change at Cycle 25 | 5.75 ± 21.02 |
| Pain - Change at Cycle 27 | 5.07 ± 17.72 |
| Pain - Change at Cycle 29 | 4.17 ± 16.11 |
| Pain - Change at Cycle 31 | 10.00 ± 23.40 |
| Pain - Change at Cycle 33 | 7.58 ± 22.81 |
| Pain - Change at Cycle 35 | 6.67 ± 21.08 |
| Pain - Change at EOT | 10.85 ± 28.99 |
| Dyspnoea - Baseline | 13.45 ± 22.01 |
| Dyspnoea - Change at Cycle 3 | 3.63 ± 22.96 |
| Dyspnoea - Change at Cycle 5 | 5.75 ± 24.06 |
| Dyspnoea - Change at Cycle 7 | 6.98 ± 24.47 |
| Dyspnoea - Change at Cycle 9 | 6.89 ± 24.38 |
| Dyspnoea - Change at Cycle 11 | 8.19 ± 26.59 |
| Dyspnoea - Change at Cycle 13 | 6.36 ± 25.37 |
| Dyspnoea - Change at Cycle 15 | 3.58 ± 24.65 |
| Dyspnoea - Change at Cycle 17 | 5.16 ± 24.54 |
| Dyspnoea - Change at Cycle 19 | 6.78 ± 26.82 |
| Dyspnoea - Change at Cycle 21 | 3.79 ± 22.98 |
| Dyspnoea - Change at Cycle 23 | 4.04 ± 20.00 |
| Dyspnoea - Change at Cycle 25 | 1.23 ± 21.64 |
| Dyspnoea - Change at Cycle 27 | 3.03 ± 22.79 |
| Dyspnoea - Change at Cycle 29 | -1.75 ± 23.50 |
| Dyspnoea - Change at Cycle 31 | 16.67 ± 28.50 |
| Dyspnoea - Change at Cycle 33 | 16.67 ± 17.57 |
| Dyspnoea - Change at Cycle 35 | 16.67 ± 23.57 |
| Dyspnoea - Change at EOT | 6.53 ± 25.79 |
| Insomnia - Baseline | 24.15 ± 28.09 |
| Insomnia - Change at Cycle 3 | 0.37 ± 27.36 |
| Insomnia - Change at Cycle 5 | -0.08 ± 28.48 |
| Insomnia - Change at Cycle 7 | -2.37 ± 29.63 |
| Insomnia - Change at Cycle 9 | -0.24 ± 29.37 |
| Insomnia - Change at Cycle 11 | 2.56 ± 28.86 |
| Insomnia - Change at Cycle 13 | 0.65 ± 26.89 |
| Insomnia - Change at Cycle 15 | -2.19 ± 27.01 |
| Insomnia - Change at Cycle 17 | -1.92 ± 25.60 |
| Insomnia - Change at Cycle 19 | 1.64 ± 23.12 |
| Insomnia - Change at Cycle 21 | 0.74 ± 25.11 |
| Insomnia - Change at Cycle 23 | -0.93 ± 33.32 |
| Insomnia - Change at Cycle 25 | -0.00 ± 28.17 |
| Insomnia - Change at Cycle 27 | -1.52 ± 24.07 |
| Insomnia - Change at Cycle 29 | -3.33 ± 30.40 |
| Insomnia - Change at Cycle 31 | -4.44 ± 41.53 |
| Insomnia - Change at Cycle 33 | -6.06 ± 32.72 |
| Insomnia - Change at Cycle 35 | -3.33 ± 33.15 |
| Insomnia - Change at EOT | 5.31 ± 32.50 |
| Appetite loss - Baseline | 17.38 ± 26.01 |
| Appetite loss - Change at Cycle 3 | 9.10 ± 28.64 |
| Appetite loss - Change at Cycle 5 | 9.02 ± 28.14 |
| Appetite loss - Change at Cycle 7 | 9.84 ± 27.80 |
| Appetite loss - Change at Cycle 9 | 9.98 ± 27.18 |
| Appetite loss - Change at Cycle 11 | 14.53 ± 28.27 |
| Appetite loss - Change at Cycle 13 | 10.67 ± 27.12 |
| Appetite loss - Change at Cycle 15 | 10.74 ± 25.90 |
| Appetite loss - Change at Cycle 17 | 8.91 ± 24.75 |
| Appetite loss - Change at Cycle 19 | 9.84 ± 24.60 |
| Appetite loss - Change at Cycle 21 | 13.04 ± 25.80 |
| Appetite loss - Change at Cycle 23 | 12.38 ± 25.67 |
| Appetite loss - Change at Cycle 25 | 11.49 ± 20.46 |
| Appetite loss - Change at Cycle 27 | 15.94 ± 22.18 |
| Appetite loss - Change at Cycle 29 | 15.00 ± 20.16 |
| Appetite loss - Change at Cycle 31 | 15.56 ± 24.77 |
| Appetite loss - Change at Cycle 33 | 15.15 ± 22.92 |
| Appetite loss - Change at Cycle 35 | 16.67 ± 17.57 |
| Appetite loss - Change at EOT | 12.03 ± 33.48 |
| Constipation - Baseline | 12.71 ± 21.61 |
| Constipation - Change at Cycle 3 | 2.42 ± 25.25 |
| Constipation - Change at Cycle 5 | 3.77 ± 26.52 |
| Constipation - Change at Cycle 7 | 2.63 ± 26.09 |
| Constipation - Change at Cycle 9 | 5.35 ± 26.68 |
| Constipation - Change at Cycle 11 | 4.42 ± 26.47 |
| Constipation - Change at Cycle 13 | 4.58 ± 25.95 |
| Constipation - Change at Cycle 15 | 4.92 ± 26.30 |
| Constipation - Change at Cycle 17 | 5.43 ± 23.35 |
| Constipation - Change at Cycle 19 | 8.33 ± 21.81 |
| Constipation - Change at Cycle 21 | 6.06 ± 18.00 |
| Constipation - Change at Cycle 23 | 9.26 ± 21.98 |
| Constipation - Change at Cycle 25 | 5.75 ± 17.97 |
| Constipation - Change at Cycle 27 | 1.45 ± 12.22 |
| Constipation - Change at Cycle 29 | 6.67 ± 20.52 |
| Constipation - Change at Cycle 31 | 22.22 ± 32.53 |
| Constipation - Change at Cycle 33 | 12.12 ± 16.82 |
| Constipation - Change at Cycle 35 | 10.00 ± 16.10 |
| Constipation - Change at EOT | 3.78 ± 27.33 |
| Diarrhoea - Baseline | 10.37 ± 19.47 |
| Diarrhoea - Change at Cycle 3 | 11.72 ± 28.16 |
| Diarrhoea - Change at Cycle 5 | 10.85 ± 28.29 |
| Diarrhoea - Change at Cycle 7 | 14.63 ± 29.94 |
| Diarrhoea - Change at Cycle 9 | 11.44 ± 26.44 |
| Diarrhoea - Change at Cycle 11 | 15.46 ± 27.26 |
| Diarrhoea - Change at Cycle 13 | 11.26 ± 24.00 |
| Diarrhoea - Change at Cycle 15 | 11.02 ± 28.02 |
| Diarrhoea - Change at Cycle 17 | 10.34 ± 21.75 |
| Diarrhoea - Change at Cycle 19 | 15.25 ± 25.76 |
| Diarrhoea - Change at Cycle 21 | 14.07 ± 24.09 |
| Diarrhoea - Change at Cycle 23 | 18.52 ± 21.74 |
| Diarrhoea - Change at Cycle 25 | 10.34 ± 22.01 |
| Diarrhoea - Change at Cycle 27 | 13.64 ± 19.68 |
| Diarrhoea - Change at Cycle 29 | 16.67 ± 25.36 |
| Diarrhoea - Change at Cycle 31 | 20.00 ± 24.56 |
| Diarrhoea - Change at Cycle 33 | 18.18 ± 22.92 |
| Diarrhoea - Change at Cycle 35 | 30.00 ± 18.92 |
| Diarrhoea - Change at EOT | 7.31 ± 24.26 |
| Financial difficulties - Baseline | 20.12 ± 30.25 |
| Financial difficulties - Change at Cycle 3 | -1.83 ± 23.80 |
| Financial difficulties - Change at Cycle 5 | -1.32 ± 24.00 |
| Financial difficulties - Change at Cycle 7 | -0.99 ± 27.68 |
| Financial difficulties - Change at Cycle 9 | -0.49 ± 26.80 |
| Financial difficulties - Change at Cycle 11 | 3.30 ± 25.64 |
| Financial difficulties - Change at Cycle 13 | 1.11 ± 27.96 |
| Financial difficulties - Change at Cycle 15 | -0.27 ± 27.94 |
| Financial difficulties - Change at Cycle 17 | 0.77 ± 27.36 |
| Financial difficulties - Change at Cycle 19 | 1.67 ± 29.70 |
| Financial difficulties - Change at Cycle 21 | 4.44 ± 25.23 |
| Financial difficulties - Change at Cycle 23 | 2.94 ± 23.74 |
| Financial difficulties - Change at Cycle 25 | -4.60 ± 19.36 |
| Financial difficulties - Change at Cycle 27 | -2.90 ± 24.44 |
| Financial difficulties - Change at Cycle 29 | 0.00 ± 21.63 |
| Financial difficulties - Change at Cycle 31 | -2.22 ± 19.79 |
| Financial difficulties - Change at Cycle 33 | -3.03 ± 17.98 |
| Financial difficulties - Change at Cycle 35 | 0.00 ± 15.71 |
| Financial difficulties - Change at EOT | 2.97 ± 27.90 |
EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and Visual Analogue Scale (VAS). EQ-5D descriptive system comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression measured on 3 levels (no problem, some problems \& severe problems) within a particular EQ-5D dimension. 5 dimensional 3-level system was converted into single index utility score. Possible values for single index utility score ranged from -0.594 (severe problems in all dimensions) to 1.0 (no problem in all dimensions) on scale where 1 represented best possible health state.
| units on a scale | Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) |
|---|---|
| Baseline | 0.77 ± 0.24 |
| Change at Cycle 3 | -0.02 ± 0.23 |
| Change at Cycle 5 | -0.03 ± 0.22 |
| Change at Cycle 7 | -0.04 ± 0.23 |
| Change at Cycle 9 | -0.05 ± 0.24 |
| Change at Cycle 11 | -0.07 ± 0.25 |
| Change at Cycle 13 | -0.05 ± 0.20 |
| Change at Cycle 15 | -0.06 ± 0.23 |
| Change at Cycle 17 | -0.05 ± 0.24 |
| Change at Cycle 19 | -0.05 ± 0.18 |
| Change at Cycle 21 | -0.09 ± 0.20 |
| Change at Cycle 23 | -0.14 ± 0.26 |
| Change at Cycle 25 | -0.08 ± 0.21 |
| Change at Cycle 27 | -0.08 ± 0.21 |
| Change at Cycle 29 | -0.08 ± 0.20 |
| Change at Cycle 31 | -0.12 ± 0.30 |
| Change at Cycle 33 | 0.02 ± 0.14 |
| Change at Cycle 35 | -0.05 ± 0.14 |
| Change at EOT | -0.11 ± 0.30 |
EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and VAS. EQ-5D descriptive system comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression measured on 3 levels (no problem, some problems \& severe problems) within a particular EQ-5D dimension. 5 dimensional 3-level system was converted into single index utility score. The VAS recorded the respondent's self-rated health on a vertical visual analogue scale. The VAS 'thermometer' has endpoints of 100 (Best imaginable health state) at the top and 0 (Worst imaginable health state) at the bottom. This information can be used as a quantitative measure of health outcome as judged by the individual respondents.
| units on a scale | Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) |
|---|---|
| Baseline | 72.81 ± 18.28 |
| Change at Cycle 3 | -1.85 ± 15.35 |
| Change at Cycle 5 | -2.15 ± 14.31 |
| Change at Cycle 7 | -2.20 ± 16.33 |
| Change at Cycle 9 | -2.74 ± 14.28 |
| Change at Cycle 11 | -3.10 ± 14.40 |
| Change at Cycle 13 | -2.36 ± 15.29 |
| Change at Cycle 15 | -1.05 ± 15.51 |
| Change at Cycle 17 | -1.91 ± 13.54 |
| Change at Cycle 19 | -3.06 ± 13.85 |
| Change at Cycle 21 | -2.13 ± 14.98 |
| Change at Cycle 23 | -5.77 ± 13.50 |
| Change at Cycle 25 | -7.28 ± 10.53 |
| Change at Cycle 27 | -4.94 ± 8.68 |
| Change at Cycle 29 | -8.80 ± 10.12 |
| Change at Cycle 31 | -6.69 ± 12.61 |
| Change at Cycle 33 | -7.90 ± 13.08 |
| Change at Cycle 35 | -8.88 ± 11.53 |
| Change at EOT | -6.67 ± 17.38 |
Collected over All AEs were collected from signature of the informed consent form up to the final visit (214 weeks) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 48/779 (6.2%) | 272/779 (34.9%) | 744/779 (95.5%) |
| Event | Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) |
|---|---|
| DiarrhoeaGastrointestinal disorders | 39/779 |
| Disease ProgressionGeneral disorders | 23/779 |
| NeutropeniaBlood and lymphatic system disorders | 14/779 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 12/779 |
| Intestinal ObstructionGastrointestinal disorders | 12/779 |
| PyrexiaGeneral disorders | 12/779 |
| HypertensionVascular disorders | 11/779 |
| VomitingGastrointestinal disorders | 10/779 |
| StomatitisGastrointestinal disorders | 9/779 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 9/779 |
| Event | Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) |
|---|---|
| DiarrhoeaGastrointestinal disorders | 464/779 |
| HypertensionVascular disorders | 369/779 |
| NauseaGastrointestinal disorders | 337/779 |
| StomatitisGastrointestinal disorders | 329/779 |
| FatigueGeneral disorders | 283/779 |
| NeutropeniaBlood and lymphatic system disorders | 277/779 |
| Decreased AppetiteMetabolism and nutrition disorders | 206/779 |
| AstheniaGeneral disorders | 192/779 |
| VomitingGastrointestinal disorders | 190/779 |
| Weight DecreasedInvestigations | 171/779 |
Safety population defined as the participants who signed the informed consent form and received at least part of one dose of study treatment.
| Age, Continuous(years) | Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) |
|---|---|
| Mean | 60.3 ± 11.0 |
| Sex: Female, Male(Participants) | Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) |
|---|---|
| Female | 314 |
| Male | 465 |
| Race/Ethnicity, Customized(Participants) | Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) |
|---|---|
| White | 631 |
| Black or African | 8 |
| American Asian | 121 |
| Other | 19 |
| Body Surface Area (BSA)(m^2) | Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) |
|---|---|
| Mean | 1.80 ± 0.23 |
| Systolic Blood Pressure(mmHg) | Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) |
|---|---|
| Mean | 126.4 ± 13.4 |
| Diastolic Blood Pressure(mmHg) | Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) |
|---|---|
| Mean | 76.4 ± 9.0 |
| Any Relevant Medical/Surgical History(Participants) | Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) |
|---|---|
| Count of participants | 640 |
| History of Thrombovascular Event and/or Presence of Cardiovascular Risk Factor(Participants) | Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) |
|---|---|
| Count of participants | 424 |
5 further baseline measures are reported on the registry.
Showing the first 100 of 179 sites across 23 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2012 to primary completion in Jan 2017, 56 months.
Results were first posted in Feb 2018, 1 year after primary completion.
Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's 56 months is above that.
Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept